

### JOUR 1 | MARDI, 27 FÉVRIER

08:00 ACCUEIL ET ENREGISTREMENT

09:00 SESSION 1

#### PROCÉDURES RÉGLEMENTAIRES ACTUELLES DANS LA RÉGION

Session Chairs: **Myriam Sedrati**, Regulatory Affairs Director North and West Africa, Merck Sharp & Dohme, Morocco

**Oumkaltoum Lahlou**, Head of Regulatory Affairs North & West Africa, Merck, Morocco

#### Maroc: Nouveau Décret lié à l'Autorisation de Mise sur le Marché: Implementation en Février 2016

**Omar Bouazza**, Director, Direction du Médicament et de la Pharmacie, Morocco

**Meriem El Baghdadi**, Head of Visas, Homologations and Authorizations, Direction du Médicament et de la Pharmacie, Morocco

#### Tunisie: Nouvelles Directives liées aux Enregistrements et Variations Implementées en Mai 2016

**Ines Fradi**, Head of Pharmacy and Medicines, Ministry of Health, Tunisia

#### Algérie: Aperçu des Réformes Majeures sur l'Environnement Réglementaire en 2017

**Yacine Sellam**, Adviser to Ministry of Health, Assistant General Manager in charge of Vaccines & Sera Development Projects, Pasteur Institute, Algeria

- Réforme des politiques de réglementation dans le cadre de "Vision 2020"
- Nouvelle Agence Nationale des Produits Pharmaceutiques (ANPP)
- PhRMA Special 301 Submission 2017
- Réforme de la Réglementation dans la Nouvelle loi sur la Santé

10:30 PAUSE CAFÉ

11:00 SESSION 2

#### VOIE À SUIVRE: RÔLE DES BONNES PRATIQUES RÉGLEMENTAIRES POUR AMÉLIORER L'ACCÈS DES PATIENTS AUX MÉDICAMENTS

Session Chair: **Nevena Miletic**, Regulatory Policy Lead – EEMEA (Eastern Europe, Middle East & Africa), F. Hoffmann-La Roche Ltd, Switzerland

#### Mise à Jour Globale sur les Bonnes Pratiques Réglementaires

**Samvel Azatyan**, Group Lead, Capacity Building, Regulatory Systems Strengthening, World Health Organization, Switzerland

#### Perspective de l'Industrie sur les Recours et les Voies Accélérées dans les Marchés Emergents

**Fabio Bisordi**, Global Head International Regulatory Policy, F. Hoffmann-La Roche, Switzerland, (on behalf of IFPMA/EFPIA)

#### Mise à Jour des Progrès Continentaux sur l'Harmonisation de la Réglementation des Médicaments en Afrique

**Paul Tanui**, Senior Programme Officer - Technical Support, AMRH Programme, South Africa

#### Table Ronde et Conclusion avec les Orateurs des Sessions 1-2

12:30 DÉJEUNER

13:30 SESSION 3

#### BIOThERAPEUTIQUES & BIOSIMILAIRES

Session Chairs: **Dounia El Maimouni**, Regulatory Affairs Manager NEMA Region (Near East, Maghreb & Africa), JANSSEN (Johnson & Johnson Company), France; **Anne Grandjacquot**, Sanofi, Head of Regulatory Affairs Africa Region, France

#### Directives Actuelles

**Peter Richardson**, Head of Quality, Specialised Scientific Disciplines Department, European Medicines Agency (EMA), European Union (participating remotely)

#### Algérie: Mise à Jour sur la Réglementation et Expérience Locale avec les Biosimilaires

**Yacine Sellam**, Adviser to Ministry of Health, Assistant General Manager in charge of Vaccines & Sera Development Projects, Pasteur Institute, Algeria

- Aperçu du Marché des Biosimilaires en Algérie
- Exemples de Projets de Fabrication Locaux
- Incertitudes Autour des Biosimilaires
- Mise à jour sur les Réglementations Spécifiques aux Biosimilaires

#### Maroc: Mise à Jour sur la Réglementation, l'Évaluation des Produits Biothérapeutiques et Biosimilaires

**Omar Bouazza**, Director, Direction du Médicament et de la Pharmacie

**Mouani Mhamed**, Head of LNCM, Laboratoire National de Contrôle du Médicament, Morocco

**Wiame Lakhilili**, Director, Pharmacist Assessor, Laboratoire National de Contrôle du Médicament, Morocco

**Rachida Soulaymani-Bencheikh**, Director, Centre Anti Poison et de Pharmacovigilance du Maroc, WHO Collaborative Center, Morocco

#### Tunisie: Mise à Jour sur la Réglementation et Expérience Locale avec les Biosimilaires

**Sameh Ben Tkhayat**, Expert Coordinator in Biosimilar Committee, DPM, Tunisia

#### Focus sur les Voies Réglementaires Mondiales et Défis pour les Biosimilaires

**Rebecca Lumsden**, Director – EM Regulatory Policy, Pfizer, United Kingdom (on behalf of IFPMA)



15:00 PAUSE CAFÉ

15:30 SESSION 4

## SECURITÉ & PHARMACOVIGILANCE

Session Chairs: **Myriam Sedrati**, Regulatory Affairs Director North and West Africa, Merck Sharp & Dohme, Morocco

**Bouchra Essaoui**, Drug Regulatory Affairs Head, Novartis Pharma, Morocco

### Pharmacovigilance: Challenges en Afrique

**Rachida Soulaymani-Bencheikh**, Director, Centre Anti Poison et de Pharmacovigilance du Maroc, WHO Collaborative Center, Morocco

### Directives de Pharmacovigilance en Tunisie

**Riadh Daghfous**, Head of Pharmacovigilance, Centre National de Pharmacovigilance, Tunisia

### Statut Mondial en Pharmacovigilance

**Djoubair Makhoulouf**, Regional Head of International Pharmacovigilance - EEMEA (Eastern Europe, Middle East & Africa), F. Hoffmann-La Roche Ltd., Switzerland

### Utilisation des Technologies Mobiles dans Différents Contextes

**Mick Foy**, Group Manager to Head of Pharmacovigilance Strategy, Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

17:00 APERITIF & NETWORKING

18:00 FIN DE LA JOURNÉE 1

## JOUR 2! MERCREDI, 28 FÉVRIER

08:30 ACCUEIL

09:00 SESSION 5

## GESTION DU CYCLE DE VIE DES PRODUITS

Session Chairs: **Hany Gamal**, Drug Regulatory Affairs Head, Middle East, Turkey and Africa Region, Boehringer-Ingelheim, United Arab Emirates

**Nevena Miletic**, Regulatory Policy Lead - EEMEA (Eastern Europe, Middle East & Africa), F. Hoffmann-La Roche Ltd, Switzerland

### Convergence Mondiale dans la Gestion du Cycle de Vie (ICH Q12 & Directive WHO)

**Kowid Ho**, Pharma Technical Regulatory Policy, F. Hoffmann-La Roche, Switzerland

### Nouvelles Directives sur la Variation au Maroc

**Omar Bouazza**, Director, Direction du Médicament et de la Pharmacie  
**Imane Haouach**, Head of Quality Assurance, Laboratoire National de Contrôle du Médicament, Morocco

### Examen des Directives sur la Variation en Tunisie

**Ines Fradi**, Head of Pharmacy and Medicines, Ministry of Health, Tunisia

### Implementation des Variations

**Catherine Gulphe**, Regulatory Affairs Manager - CMC & Devices, Sanofi, France (on behalf of IFPMA)

### Table Ronde avec Questions/Réponses

10:30 PAUSE CAFÉ

11:00 SESSION 6

## MÉDICAMENTS SANS ORDONNANCE: STATUT ET ENREGISTREMENT

Session Chair: **Anne Grandjacquot**, Sanofi, Head of Regulatory Affairs Africa Region, France

**Kamal Ubaysi**, Chairman of the Middle East North Africa Self Medication Industry and Global Head of Integration projects, Sanofi, France

### Mise à jour sur le statut OTC européen

**Emma Paulino**, Interim CEO, International Pharmaceutical Federation (FIP), The Netherlands

### Mise à jour sur le statut OTC au Moyen-Orient

**Mearal Hussein**, Interim CEO, Head of Regulatory Middle East, GSK Consumer Health, Egypt (on behalf of IFPMA)

### Table Ronde avec Questions/Réponses sur l'Automédication

### Intervenants invités:

**Ines Fradi**, Head of Pharmacy and Medicines, Ministry of Health, Tunisia

**Lotfi Benbahmed**, President, National Order of Pharmacists of Algeria, Algeria

**Yacine Sellam**, Adviser to Ministry of Health, Assistant General Manager in charge of Vaccines & Sera Development Projects, Pasteur Institute, Algeria

**Kamal Ubaysi**, Chairman of the Middle East North Africa Self Medication Industry and Global Head of Integration projects, Sanofi, France  
Morocco Representative Invited

12:30 DÉJEUNER

13:30 TABLE RONDE FINALE : POINTS CLÉS À RETENIR

Session Chair: **Dounia El Maimouni**, Regulatory Affairs Manager NEMA Region (Near East, Maghreb & Africa), JANSSEN (Johnson & Johnson Company), France

**Nevena Miletic**, Regulatory Policy Lead - EEMEA (Eastern Europe, Middle East & Africa), F. Hoffmann-La Roche Ltd, Switzerland

**Omar Bouazza**, Director, Direction du Médicament et de la Pharmacie, Morocco

**Samvel Azatyan**, Group Lead, Capacity Building, Regulatory Systems Strengthening, World Health Organization, Switzerland

**Yacine Sellam**, Adviser to Ministry of Health, Assistant General Manager in charge of Vaccines & Sera Development Projects, Pasteur Institute, Algeria

**Ines Fradi**, Head of Pharmacy and Medicines, Ministry of Health, Tunisia

**Paul Tanui**, Senior Programme Officer - Technical Support, AMRH Programme, NEPAD, South Africa  
EMA Representative Invited

15:00 CAFÉ

15:30 FIN DE LA CONFÉRENCE

# REGISTRATION FORM | ID# 18114T1



1st Regional Conference on Regulatory Harmonisation  
27-28 February 2018 | Hotel Sofitel, Casablanca, Morocco

## Registration form for Moroccan citizens.

CATEGORY	Member *	Non-Member*
Industry	€ 950.00 <input type="checkbox"/>	€ 950.00 <input type="checkbox"/>
Government/Charitable/Non-profit/Academia (Full-Time)	€ 715.00 <input type="checkbox"/>	€ 870.00 <input type="checkbox"/>

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee. Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to availability. Please contact DIA in Basel for more information.  
Registration fee includes: refreshments, lunches, reception and meeting materials.

**20% Moroccan VAT will be added to the fees (please see invoice confirmation for details of payment)**

**10% withholding Tax to be paid directly to the authorities. Please send a confirmation of this payment to DIA.**

Payment due 30 days after registration and must be paid in full by commencement of the event.

**TOTAL AMOUNT DUE: € \_\_\_\_\_**

Please chose your preferred language and we will adapt the material you receive at the conference accordingly:

English  Français

## ATTENDEE DETAILS

PLEASE COMPLETE IN BLOCK CAPITAL LETTERS OR MAKE REGISTRATION EVEN SIMPLER BY ATTACHING THE ATTENDEE'S BUSINESS CARD HERE

Prof  Dr  Ms  Mr

Last Name

First Name

Company

Job Title

Address

Postal Code  City

Country

Telephone

Fax

Attendee email required to access presentations

Please provide your European VAT number

## PAYMENT METHODS

**Credit cards:** Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

Please charge my  VISA  MC  AMEX

Card N°

Exp. Date

Cardholder's Name

**Bank transfers:** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID# 18114T1 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA in Basel.**

By signing below, I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking [here](#).

Date

Signature

## DIA MEMBERSHIP

Join DIA now to qualify to save on future events and to receive all the benefits of membership. Visit [www.DIAglobal.org](http://www.DIAglobal.org) and click on Membership for more details.

DIA offers one year complimentary membership against event registration at non-member rate

I do not want complimentary membership

## TERMS AND CONDITIONS

### Cancellations

All cancellations must be made in writing and be received at the DIA office in Basel four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

For cancellations after this date, or if the delegate fails to attend the meeting, no refund of fees will be given and be responsible for the full registration fee. DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled, DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

### Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA office in Basel of any such substitutions as soon as possible.

### Photography and Video Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

The DIA will be pleased to assist you with your registration from Monday to Friday between 08:30 and 17:00 CET.

Email [Basel@DIAglobal.org](mailto:Basel@DIAglobal.org)

Tel. +41 61 225 51 51

Fax +41 61 225 51 52

Web [www.DIAglobal.org](http://www.DIAglobal.org)

Mail DIA, Kuechengasse 16, 4051 Basel, Switzerland